Skip to main content
Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: Targeting SERT promotes tryptophan metabolism: mechanisms and implications in colon cancer treatment

Fig. 7

Anti-tumor effect of a combination SERT inhibition with dietary trp restriction or trametinib in vitro. a Proliferation assays using the Cell Counting Kit-8 in SW480 and HCT116 cells transfected with siSERT or treated with sertraline in the presence or absence of Trp (75 uM) at day 2. Data were presented as the mean ± SD. b Colon cancer cells (SW480 and HCT116) were starved in serum-free medium for 24 h and stimulated with EGF (25-100 nM) for another 24 h or directly treated with trametinib (25-100 nM) for 24 h, after which WB analysis of SLC1A5 was performed. c WB for SLC1A5, c-Myc, Cyclin D1, cleaved PARP and BCL-XL in SW480 and HCT116 cells treated with 15 μM sertraline with or without trametinib (75 nM). d Proliferation assays using the Cell Counting Kit-8 in SW480 and HCT116 cells transfected with siSERT or treated with sertraline in the presence or absence of trametinib at day 2. Data are presented as the mean ± SD. e SW480 and HCT116 cells were incubated with DMSO, sertraline (2 μM), trametinib (25 nM) and combined treatment for 7 d, respectively. Cell proliferation abilities were evaluated by the colony formation assay

Back to article page